Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3640169 | 0.83 | AOC3 (0.44) | — | |
| SCHEMBL10441226 | 0.82 | AOC3 (0.42) | — | |
| SCHEMBL2789642 | 0.81 | HTR2A (0.53) | HTR2AHTR2CKCNH2DRD2CCNT1 | |
| SCHEMBL1237690 | 0.80 | MAOB (0.49) | HTR2AHTR2CKCNH2 | |
| SCHEMBL29688552 | 0.80 | MAOB (0.49) | HTR2AHTR2CKCNH2 | |
| SCHEMBL20284651 | 0.80 | ROCK1 (0.49) | CCNT1CDK9 | |
| SCHEMBL20284413 | 0.80 | ROCK1 (0.49) | CCNT1CDK9PARP1 | |
| SCHEMBL73543 | 0.79 | AOC3 (0.47) | — | |
| SCHEMBL2005837 | 0.77 | CCNT1 (0.48) | CCNT1CDK9 | |
| SCHEMBL2013169 | 0.77 | CCNT1 (0.48) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10912786-B2 | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same | CORNELL UNIVERSITY (US) | 2021-02-09 | — | — | US | claimed |
| EP-0683166-B1 | 3-Indolylpiperidines | MERCK PATENT GMBH (DE) | 1998-10-28 | — | — | EP | claimed |
| US-5693655-A | 3-indolylpiperidines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-12-02 | — | — | US | claimed |
| EP-0683166-A1 | 3-Indolylpiperidines | MERCK PATENT GmbH (DE) | 1995-11-22 | — | — | EP | claimed |
| EP-0465398-B1 | Novel indole derivatives | LUNDBECK & CO AS H (DK) | 1994-12-14 | — | — | EP | claimed |
| EP-0465398-A2 | Novel indole derivatives | H. LUNDBECK A/S (DK) | 1992-01-08 | — | — | EP | claimed |
| EP-0071520-B1 | 3-PIPERIDINYLINDOLE DERIVATIVES, THEIR SALTS AND PREPARATION, THEIR USE IN MEDICINES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1985-09-04 | — | — | EP | claimed |
| US-4447438-A | Dopaminergic stimulating piperidin-3-yl-indoles | ROUSSEL UCLAF (FR) | 1984-05-08 | — | — | US | claimed |
| EP-0071520-A1 | 3-Piperidinylindole derivatives, their salts and preparation, their use in medicines and pharmaceutical preparations containing them | ROUSSEL-UCLAF (FR) | 1983-02-09 | — | — | EP | claimed |
| JP-7291969-A | — | — | None | — | — | JP | disclosed |
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-30 | — | — | US | disclosed |
| EP-2693883-B1 | SILYL MONOMERS CAPABLE OF MULTIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | UNIV CORNELL (US) | 2018-12-26 | — | — | EP | disclosed |
| US-20150274661-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-4447438-A | Dopaminergic stimulating piperidin-3-yl-indoles | ROUSSEL UCLAF (FR) | 1984-05-08 | — | — | US | disclosed |
| US-4447438-A | Dopaminergic stimulating piperidin-3-yl-indoles | ROUSSEL UCLAF (FR) | 1984-05-08 | — | — | US | disclosed |
| EP-0071521-A2 | Pyrid-3-yl or piperidin-3-yl-oxo-2-indole derivatives, their salts, process for their preparation, compositions containing them and their uses as medicines | ROUSSEL-UCLAF (FR) | 1983-02-09 | — | — | EP | disclosed |
| EP-0071521-A2 | Pyrid-3-yl or piperidin-3-yl-oxo-2-indole derivatives, their salts, process for their preparation, compositions containing them and their uses as medicines | ROUSSEL-UCLAF (FR) | 1983-02-09 | — | — | EP | disclosed |
| EP-0071520-A1 | 3-Piperidinylindole derivatives, their salts and preparation, their use in medicines and pharmaceutical preparations containing them | ROUSSEL-UCLAF (FR) | 1983-02-09 | — | — | EP | disclosed |
| EP-0071520-A1 | 3-Piperidinylindole derivatives, their salts and preparation, their use in medicines and pharmaceutical preparations containing them | ROUSSEL-UCLAF (FR) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382919-A1 | OXA- IBOGAINE INSPIRED ANALOGUES FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRIA4, GRIA3, GRIN3A | HTR2A 133/4885HTR2C 126/4885KCNH2 326/4885 |
| US-10912786-B2 | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same | STIM1, STAMBP, ILK | HTR2A 4491/4885HTR2C 4749/4885KCNH2 4795/4885 |
| US-20150274661-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | APP, BACE1, IAPP | HTR2A 57/4885HTR2C 413/4885KCNH2 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.